Toggle Offcanvas
...
 
Tocilizumab Tenders

Tocilizumab Tenders

View Tocilizumab tenders, RFPs and contracts. Bid on readily available Tocilizumab tenders with the best and most comprehensive tendering platform, since 2002.

Bidding for Tocilizumab tenders is extremely lucrative for companies of all sizes. Tendering authorities and private companies release thousands of contracts worth millions for procurement of Tocilizumab.

Global Tenders stands out as the largest platform dedicated to pharmaceutical tenders and government contracts. Boasting over 20 years of experience in the tender business, GlobalTenders offers the most extensive and reliable Tenders/RFPs/Contracts Database available. The platform aggregates contracts from both public and private sources, connecting with a vast network of over half a million buyers. Employing advanced artificial intelligence, our meticulous process involves gathering information from over a hundred thousand sources. The data is then intelligently categorized into thousands of subcategories for easy filtering and presenting it in a user-friendly format for quick comprehension.

In addition to tender information, we offer in-depth Tocilizumab market analysis, bid consultancy services, and insights into top bidders and winners.

Sign up now to get instant access to unlimited Tocilizumab tenders, advanced search filters, market analysis, industry trends, tender training and 24/7 customer support.

26 Live Notices for Tocilizumab Tenders

Showing 1 to 20

Conduct, Supervision And Management Of A Non-Commercial Clinical Trial
country Poland
posting date05 Feb 2025
deadline20 Feb 2025
23/S/24/Su/Dg/A/Am12 - Establish The Conditions For The Supply Of Biological/Biosimilar Medicines For Human Use, In Order To Cover The Healthcare Needs Of The Centres Dependent On The Canary Islands Health Service.
country Spain
posting date04 Feb 2025
deadline11 Mar 2025
Purchase And Delivery Of Medicinal Products Used In Drug And Chemotherapy Programs
country Poland
posting date23 Jan 2025
deadline10 Feb 2025
23/S/24/Su/Dg/A/Am12 - Establish The Conditions For The Supply Of Biological/Biosimilar Medicines For Human Use, In Order To Cover The Healthcare Needs Of The Centres Dependent On The Canary Islands Health Service.
country Spain
posting date20 Jan 2025
deadline18 Feb 2025
Environmentally Friendly Supply Of Biological Human Medicines With Biosimilars For Public Health Centres In Valencia
country Spain
posting date30 Dec 2024
deadline01 Oct 2025
Conclusion Of A Non-Exclusive Drug Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Code Book V By Means Of An Open-House Model For The Active Ingredient Tocilizumab (Atc Code According To Who: L04Ac07)
country Germany
posting date11 Nov 2024
deadline31 Dec 2025
Conclusion Of A Non-Exclusive Drug Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Code Book V By Means Of An Open-House Model For The Active Ingredient Tocilizumab (Atc Code According To Who: L04Ac07)
country Germany
posting date11 Nov 2024
deadline31 Dec 2025
Conclusion Of A Non-Exclusive Drug Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Code Book V By Means Of An Open-House Model For The Active Ingredient Tocilizumab (Atc Code According To Who: L04Ac07)
country Germany
posting date11 Nov 2024
deadline31 Dec 2025
Open House Award 2024-4
country Germany
posting date22 Oct 2024
deadline30 Nov 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Tocilizumab (Excl. Infusion Solution Concentrate), Atc L04Ac07 (Obo) For The Period 01.10.2024 - 30.11.2025
country Germany
posting date19 Aug 2024
deadline05 Oct 2025
Conclusion Of Non-Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Tocilizumab
country Germany
posting date22 May 2024
deadline11 May 2026
Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Tocilizumab
country Germany
posting date22 May 2024
deadline11 May 2026
Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Tocilizumab
country Germany
posting date21 May 2024
deadline11 May 2026
Conclusion Of A Non-Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For The Active Ingredient Tocilizumab, Atc L04Ac07 For The Period December 1St, 2023 - November 30Th, 2024 (Plus Extension Option 1X12 Months)
country Germany
posting date20 Oct 2023
deadline05 Oct 2025
Conclusion Of Non-Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8/130C Paragraph 1 Sgb V For Drugs With The Active Ingredient Tocilizumab (L04Ac07) As Part Of A So-Called Open House Model.
country Germany
posting date11 Oct 2023
deadline30 Sep 2025
Conclusion Of Non-Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8/130C Paragraph 1 Sgb V For Drugs With The Active Ingredient Tocilizumab (L04Ac07) As Part Of A So-Called Open House Model.
country Germany
posting date10 Oct 2023
deadline30 Sep 2025
Oh-Biologika-2023-29 - Tocilizumab
country Germany
posting date06 Oct 2023
deadline31 Oct 2025
Oh-Biologika-2023-29 - Tocilizumab
country Germany
posting date05 Oct 2023
deadline31 Oct 2025
Conclusion Of A Non-Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For Drugs With The Active Ingredient Tocilizumab (Atc Code: L04Ac07).
country Germany
posting date23 Sep 2023
deadline27 Aug 2025
Completion Of A Non-Exclusive Discount Contract According To Section 130A Paragraph 8 Sgb V For Tocilizumab, Atc Code: L04Ac07 For The Period From November 1St, 2023 To October 31St, 2025
country Germany
posting date23 Sep 2023
deadline05 Sep 2025

Share Share this page